Discovering biased antagonists of CXCR2 as drug leads for acute lung injury
Active Grant Awarded
- Award ID
- R41HL187112
- Recipient
-
Biagon, Inc. UEI KC22MJKDF1R1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $349,997
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 21% complete
- Place of performance
- Chicago, IL 60608, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded Biagon, Inc. $349,997 on September 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) through Grant R41HL187112. The award funds Phase I work to discover biased antagonists of the chemokine receptor CXCR2 as drug leads for acute lung injury, with a long-term objective of developing a drug that reduces inflammation from acute lung injury while avoiding antagonist tolerance. Biagon will train a machine learning model for CXCR2 signaling efficacy on G protein antagonism and β-arrestin recruitment data from known small molecule CXCR2 antagonists, updating the model as data accumulates. The recipient will run a large-scale virtual screen against a CXCR2 structure that favors β-arrestin signaling, purchase top hits as liquid stock, and test them in a high-throughput primary screen for G protein antagonism. Hits from the primary screen will undergo a secondary screen using concentration response curves for G protein antagonism and β-arrestin recruitment. Confirmed hits will then be optimized into drug leads through design-make-test-analyze cycles, with analog design accelerated by computational chemistry and the machine learning model. Biagon's underlying method interprets molecular dynamics simulations to reveal structural mechanisms of 7TMR activation and compute signaling efficacies along multiple pathways. Place of performance is Chicago, Illinois 60608, and the ultimate completion date is August 31, 2027.
Description
- Abstract
- The long-term objective of this project is to develop a drug that treats inflammation due to acute lung injury and maintains clinical efficacy by avoiding the side effect of antagonist tolerance. Chemokine receptors are 7 transmembrane helix receptors (7TMRS), traditionally known as G protein coupled receptors, that detect inflammatory chemokines and transduce signals into the cell along G protein and Β-arrestin pathways. IT has been shown that biased antagonists that block G protein but allow Β-arrestin signaling avoid antagonist tolerance. In phase I, biased antagonists for the chemokine receptor CXCR2 with micromolar potency will be discovered. To guide the identification of biased antagonists, a long-term objective of this project is to develop a machine learning model for CXCR2 signaling efficacy. Biagon INC. Has developed a machine learning method that interprets molecular dynamics simulations to unveil structural mechanisms of 7TMR activation and to compute signaling efficacies along multiple pathways. To train the machine learning model for CXCR2, G protein antagonism and Β-arrestin recruitment data for known small molecule CXCR2 antagonists will be collected. The model will be updated throughout the project as more data is collected. To discover biased antagonists, a large-scale virtual screen will be performed against a structure of CXCR2 that favors Β-arrestin signaling determined with the ML model. Top hits will be purchased in the form of liquid stock and tested in a high-throughput primary screen for G protein antagonism. Hits from the primary screen will be tested in a secondary screen involving concentration response curves for G protein antagonism and Β-arrestin recruitment. After hits are confirmed, they will be optimized into drug leads through several design-make-test- analyze cycles. Analog design will be accelerated using computational chemistry and the ML model. The compounds will be synthesized and tested to obtain signaling potency and efficacy. Upon successful completion of sttr phase I, one or more drug leads will be identified that can be optimized to nanomolar potency and tested for in vivo efficacy through phase II funding. Phase I would also be a proof of principle for a HIT discovery workflow that would be suitable for designing potent biased ligands of 7TMRS, which are targeted by about one third of all drugs.
Quick answers
Who received award R41HL187112?
R41HL187112 was awarded to Biagon, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R41HL187112 worth?
$349,997 has been obligated on R41HL187112.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award